Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor

作者: H Singh , J S E Moyes , M H Huls , L J N Cooper

DOI: 10.1038/CGT.2014.69

关键词:

摘要: T cells can be reprogrammed to redirect specificity tumor-associated antigens (TAAs) through the enforced expression of chimeric antigen receptors (CARs). The prototypical CAR is a single-chain molecule that docks with TAA expressed on cell surface and, in contrast T-cell receptor complex, recognizes target independent human leukocyte antigen. bioprocessing generate CAR(+) has been reduced clinical practice based two common steps are accomplished compliance current good manufacturing practice. These (1) gene transfer stably integrate using viral and nonviral approaches (2) activating for proliferation by crosslinking CD3 or antigen-driven numeric expansion propagating (AaPCs). Here, we outline our approach Sleeping Beauty system selective propagation CD19-specific AaPCs.

参考文章(55)
Amer M. Najjar, Judy S.E. Moyes, Laurence J.N. Cooper, DNA Plasmids for Non-viral Gene Therapy of Cancer Wiley-Blackwell. pp. 39- 59 ,(2014) , 10.1002/9781118501665.CH3
Yangbing Zhao, Qiong J. Wang, Shicheng Yang, James N. Kochenderfer, Zhili Zheng, Xiaosong Zhong, Michel Sadelain, Zelig Eshhar, Steven A. Rosenberg, Richard A. Morgan, A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. Journal of Immunology. ,vol. 183, pp. 5563- 5574 ,(2009) , 10.4049/JIMMUNOL.0900447
David Rushworth, Bipulendu Jena, Simon Olivares, Sourindra Maiti, Neima Briggs, Srinivas Somanchi, Jianliang Dai, Dean Lee, Laurence JN Cooper, None, Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. Journal of Immunotherapy. ,vol. 37, pp. 204- 213 ,(2014) , 10.1097/CJI.0000000000000032
S. Maiti, H. Singh, T. Mi, J. Roszik, B. Rabinovich, S. Olivares, J. Krishnamurthy, L. Zhang, A. M. Najjar, M. H. Huls, D. A. Lee, R. E. Champlin, D. P. Kontoyiannis, L. J. N. Cooper, P. R. Kumaresan, P. R. Manuri, N. D. Albert, Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection Proceedings of the National Academy of Sciences of the United States of America. ,vol. 111, pp. 10660- 10665 ,(2014) , 10.1073/PNAS.1312789111
James N. Kochenderfer, Steven A. Feldman, Yangbing Zhao, Hui Xu, Mary A. Black, Richard A. Morgan, Wyndham H. Wilson, Steven A. Rosenberg, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. Journal of Immunotherapy. ,vol. 32, pp. 689- 702 ,(2009) , 10.1097/CJI.0B013E3181AC6138
Maria R Parkhurst, James C Yang, Russell C Langan, Mark E Dudley, Debbie-Ann N Nathan, Steven A Feldman, Jeremy L Davis, Richard A Morgan, Maria J Merino, Richard M Sherry, Marybeth S Hughes, Udai S Kammula, Giao Q Phan, Ramona M Lim, Stephen A Wank, Nicholas P Restifo, Paul F Robbins, Carolyn M Laurencot, Steven A Rosenberg, T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis Molecular Therapy. ,vol. 19, pp. 620- 626 ,(2011) , 10.1038/MT.2010.272
Murrium Ahmad, RobertC. Rees, SelmanA. Ali, Escape from immunotherapy: possible mechanisms that influence tumor regression/progression Cancer Immunology, Immunotherapy. ,vol. 53, pp. 844- 854 ,(2004) , 10.1007/S00262-004-0540-X
S Nayak, R W Herzog, Progress and prospects: immune responses to viral vectors Gene Therapy. ,vol. 17, pp. 295- 304 ,(2010) , 10.1038/GT.2009.148
Shoji Saito, Yozo Nakazawa, Akane Sueki, Kazuyuki Matsuda, Miyuki Tanaka, Ryu Yanagisawa, Yasuhiro Maeda, Yuko Sato, Seiichi Okabe, Takeshi Inukai, Kanji Sugita, Matthew H. Wilson, Cliona M. Rooney, Kenichi Koike, Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome–positive acute lymphoblastic leukemia Cytotherapy. ,vol. 16, pp. 1257- 1269 ,(2014) , 10.1016/J.JCYT.2014.05.022